Your browser is no longer supported. Please, upgrade your browser.
HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite Help
publish chart | save to portfolio | create alert Type: candle | line | advanced | interactive | perf    Timeframe: intraday | daily | weekly | monthly
MYGN Myriad Genetics, Inc. daily Stock Chart
MYGN [NASD]
Myriad Genetics, Inc.
Services | Research Services | USA
statements
Index- P/E- EPS (ttm)-0.36 Insider Own1.10% Shs Outstand81.07M Perf Week-12.94%
Market Cap992.30M Forward P/E17.61 EPS next Y0.70 Insider Trans0.14% Shs Float73.24M Perf Month-29.08%
Income-26.20M PEG- EPS next Q0.02 Inst Own- Short Float16.07% Perf Quarter-54.41%
Sales813.40M P/S1.22 EPS this Y-95.70% Inst Trans0.03% Short Ratio10.47 Perf Half Y-57.40%
Book/sh14.48 P/B0.85 EPS next Y67.47% ROA-1.70% Target Price20.29 Perf Year-61.94%
Cash/sh1.75 P/C7.01 EPS next 5Y8.10% ROE-2.40% 52W Range9.24 - 48.40 Perf YTD-55.05%
Dividend- P/FCF24.08 EPS past 5Y-51.50% ROI0.90% 52W High-74.71% Beta1.45
Dividend %- Quick Ratio3.00 Sales past 5Y1.80% Gross Margin75.60% 52W Low32.47% ATR1.48
Employees2600 Current Ratio3.30 Sales Q/Q-10.00% Oper. Margin-3.60% RSI (14)34.07 Volatility8.86% 12.38%
OptionableYes Debt/Eq0.21 EPS Q/Q-428.20% Profit Margin-3.20% Rel Volume0.96 Prev Close13.31
ShortableYes LT Debt/Eq0.21 EarningsMay 07 AMC Payout- Avg Volume1.12M Price12.24
Recom3.10 SMA20-8.45% SMA50-34.94% SMA200-52.56% Volume1,084,837 Change-8.04%
Sep-26-19Downgrade BofA/Merrill Neutral → Underperform $30 → $28
Aug-14-19Downgrade Piper Jaffray Overweight → Neutral $45 → $40
Aug-02-19Upgrade BofA/Merrill Underperform → Neutral
Aug-01-19Upgrade Barclays Underweight → Equal Weight $18 → $40
Jul-29-19Downgrade Needham Strong Buy → Hold
Jul-09-19Downgrade Cowen Outperform → Market Perform
Mar-12-19Reiterated Needham Strong Buy $37 → $41
Jan-03-19Initiated Needham Strong Buy $36
Nov-30-18Upgrade Goldman Sell → Neutral
Oct-10-18Upgrade Piper Jaffray Neutral → Overweight
Jul-11-18Upgrade Morgan Stanley Equal-Weight → Overweight
Mar-21-18Upgrade Morgan Stanley Underweight → Equal-Weight
Jan-29-18Initiated Goldman Sell $32
Jan-22-18Reiterated Barclays Equal Weight $30 → $35
Jan-05-18Initiated BTIG Research Buy $41
Oct-02-17Resumed Leerink Partners Mkt Perform $31
Aug-09-17Reiterated Barclays Equal Weight $28 → $26
Feb-08-17Upgrade Ladenburg Thalmann Sell → Neutral
Jan-18-17Initiated Deutsche Bank Sell $15
Oct-10-16Downgrade Ladenburg Thalmann Neutral → Sell
Mar-30-20 07:05AM  Myriad Seeks Japanese Regulatory Approval for its BRACAnalysis® Diagnostic System in People with Advanced Pancreatic and Prostate Cancer GlobeNewswire
Mar-23-20 07:13AM  A Look At The Intrinsic Value Of Myriad Genetics, Inc. (NASDAQ:MYGN) Simply Wall St.
07:05AM  Myriad Announces Board of Directors Leadership Transition GlobeNewswire
Mar-19-20 09:46AM  Myriad Grows Internationally, Hereditary Cancer Revenues Soft Zacks +24.13%
Mar-18-20 07:05AM  NCCN Updates Professional Guidelines Recommending Biomarker Testing for Unfavorable Intermediate and High-Risk Patients with Prostate Cancer GlobeNewswire -5.42%
Mar-07-20 11:31AM  Myriad (MYGN) Down 44.1% Since Last Earnings Report: Can It Rebound? Zacks
Mar-04-20 08:29AM  Zacks.com featured highlights include: Envestnet, First Majestic Silver, Myriad Genetics, Vericel and Casella Waste Systems Zacks +5.74%
Mar-03-20 09:28AM  Dump These 5 Toxic Stocks Right Away Zacks -7.42%
Feb-28-20 06:58AM  The Zacks Analyst Blog Highlights: Abbott Laboratories, Myriad Genetics, LabCorp, QIAGEN and Thermo Fisher Zacks
Feb-17-20 04:02PM  Edited Transcript of MYGN earnings conference call or presentation 6-Feb-20 9:30pm GMT Thomson Reuters StreetEvents
09:31AM  Steer Clear Of These 5 Toxic Stocks Before It's Too Late Zacks
07:46AM  Myriad Genetics (MYGN) Releases Favorable Prolaris Results Zacks
Feb-14-20 07:05AM  New Study Demonstrates the Ability of Prolaris® to Predict Which Men With Prostate Cancer Will Benefit from Multi-Modality Therapy GlobeNewswire
Feb-13-20 10:36AM  Myriad Genetics (MYGN) Files for myChoice CDx Test sPMA Zacks
Feb-12-20 07:05AM  Myriad Genetics to Present at the SVB Leerink Global Healthcare Conference GlobeNewswire
Feb-11-20 07:05AM  Myriad Submits sPMA for myChoice® CDx with Lynparza® in First-Line Maintenance Therapy in Advanced Ovarian Cancer GlobeNewswire
Feb-07-20 08:08PM  The Law Offices of Frank R. Cruz Announces Investigation on Behalf of Myriad Genetics, Inc., Investors (MYGN) Business Wire -28.23%
09:56AM  Myriad Genetics (MYGN) Misses Q2 Earnings & Revenue Estimates Zacks
08:58AM  Myriad Genetics Stock Is Tanking After Earnings. The CEO Is Out. Barrons.com
07:32AM  The Daily Biotech Pulse: Assertio To Sell Opioid Pain Drug, Milestone Payment For Aduro, Myriad Genetics CEO Resigns Benzinga
07:23AM  What Did Myriad Genetics, Inc.'s (NASDAQ:MYGN) CEO Take Home Last Year? Simply Wall St.
Feb-06-20 06:15PM  Myriad Genetics (MYGN) Misses Q2 Earnings and Revenue Estimates Zacks
04:05PM  Myriad Genetics Reports Fiscal Second-Quarter 2020 Financial Results GlobeNewswire
04:05PM  Myriad Announces Leadership Transition GlobeNewswire
02:30PM  Myriad Genetics, Inc. to Host Earnings Call ACCESSWIRE
Jan-30-20 07:05AM  Myriad to Announce Fiscal Second-Quarter 2020 Financial Results on February 6, 2020 GlobeNewswire
Jan-28-20 12:31PM  Earnings Preview: Myriad Genetics (MYGN) Q2 Earnings Expected to Decline Zacks
Jan-22-20 06:36PM  Myriad Submits sPMA for myChoice® CDx with Zejula® in First-Line Platinum Responsive Advanced Ovarian Cancer GlobeNewswire
Jan-21-20 07:05AM  Myriad Submits sPMA for BRACAnalysis® CDx as a Companion Diagnostic for Lynparza® in Metastatic Castration-resistant Prostate Cancer GlobeNewswire
Jan-14-20 07:05AM  Dr. Thomas P. Slavin Named Senior Vice President of Medical Affairs for Myriad Oncology GlobeNewswire
Jan-07-20 09:35AM  Myriad Genetics' GUIDED Clinical Trial Outcome Encouraging Zacks
Jan-06-20 04:05PM  Myriad Genetics to Present at the J.P. Morgan 2020 Healthcare Conference GlobeNewswire
07:05AM  New Publication Demonstrates GeneSight® Improved All Clinical Outcomes Using HAM-D6 Analysis in Large Prospective GUIDED Study GlobeNewswire
Dec-31-19 11:12AM  Myriad Genetics' Cancer Companion Diagnostic Test Gets FDA Nod Zacks
Dec-30-19 04:29PM  Stocks mark steepest slide in about 4 weeks with one trading day left in 2019 MarketWatch
04:08PM  This Genetic-Testing Stock Popped, Then Slipped, On Its FDA Approval Investor's Business Daily
12:37PM  INVESTOR ALERT: Kirby McInerney LLP Launches Investigation of Myriad Genetics (MYGN) for Possible Breaches of Fiduciary Duty by Certain Officers and Directors Business Wire
08:41AM  Nio Stock Is Soaring, Myriad Genetics Jumps, as the Dow Holds Its Ground Barrons.com
07:45AM  Myriad Genetics's stock surges after FDA approval of diagnostic test for pancreatic cancer MarketWatch
07:05AM  Myriad Receives FDA Approval of BRACAnalysis CDx® as Companion Diagnostic for Lynparza® (olaparib) In Patients with Germline BRCA-mutated Metastatic Pancreatic Cancer GlobeNewswire
03:54AM  Myriad Genetics Spikes on FDA Approval of Pancreatic Cancer Diagnostic Test TheStreet.com
Dec-24-19 10:11AM  Does Myriad Genetics's (NASDAQ:MYGN) Share Price Gain of 47% Match Its Business Performance? Simply Wall St. +10.34%
Dec-23-19 06:18PM  Myriad Genetics Is Tumbling After The Wall Street Journal Highlighted the Risks of Acting on Genetic Testing Barrons.com -9.47%
Dec-19-19 10:22PM  Hedge Funds Are Dumping Myriad Genetics, Inc. (MYGN) Insider Monkey
07:05AM  Myriad Genetics Board Member, S. Louise Phanstiel, Recognized by WomenInc. Magazine in 2019 List of Most Influential Corporate Directors GlobeNewswire
Dec-17-19 09:03AM  Myriad Genetics Presents Trial Outcomes in Breast Health Zacks
Dec-14-19 07:05AM  Myriads Polygenic Risk Score Personalizes Risk of Breast Cancer for Woman with a Genetic Mutation in Important Breast Cancer Genes GlobeNewswire
Dec-06-19 02:41PM  Hedge Funds Love Tri Pointe Group Inc (TPH) Way More Than These 3 Stocks Insider Monkey
Dec-05-19 09:24AM  Myriad Genetics Reports Favorable Study Result on Prequel Zacks
Dec-04-19 11:30AM  Myriad (MYGN) Up 18.4% Since Last Earnings Report: Can It Continue? Zacks
08:58AM  Myriad shares fall despite positive results on prenatal test MarketWatch
07:05AM  Myriads Prequel Prenatal Screen has Superior Sensitivity in Women with High BMI Undergoing Non-Invasive Prenatal Screening GlobeNewswire
Dec-03-19 07:05AM  Myriad Genetics to Present Multiple Studies on Breast Cancer at the 2019 San Antonio Breast Cancer Symposium GlobeNewswire
Nov-26-19 12:50PM  CLASS ACTION UPDATE for OSTK, MYGN and GRUB: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders ACCESSWIRE
11:00AM  FINAL DEADLINE TODAY: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Myriad Genetics, Inc. and Encourages Investors with Losses in Excess of $250,000 to Contact the Firm ACCESSWIRE
10:21AM  The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of SEE, MYGN, ZEN and YJ GlobeNewswire
02:00AM  MYGN DEADLINE TODAY: HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Alerts Myriad Genetics (MYGN) Investors of Todays Deadline to Move for Lead Plaintiff ACCESSWIRE
Nov-25-19 04:50PM  FINAL DEADLINE TOMORROW: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Myriad Genetics, Inc. and Encourages Investors with Losses in Excess of $250,000 to Contact the Firm ACCESSWIRE +6.36%
03:15PM  The Gross Law Firm Announces Class Actions on Behalf of Shareholders of MYGN, CC and ET ACCESSWIRE
02:15PM  FINAL DEADLINE ALERT: HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Myriad Genetics (MYGN) Investors Who Suffered Significant Losses to Contact Its Attorneys, Application Deadline Tomorrow ACCESSWIRE
12:30PM  SHAREHOLDER ALERT: MYGN TEUM ACB: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines ACCESSWIRE
11:09AM  Myriad Shareholder Alert: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Myriad Genetics, Inc. To Contact The Firm Newsfile
09:51AM  DEADLINE ALERT - Myriad Genetics, Inc. (MYGN) - Bronstein, Gewirtz & Grossman, LLC Reminds Shareholders of Class Action and Lead Plaintiff Deadline: November 26, 2019 ACCESSWIRE
09:28AM  MYGN FINAL DEADLINE: ROSEN LAW FIRM Reminds Myriad Genetics, Inc. Investors of Tuesday Deadline in Securities Class Action MYGN GlobeNewswire
09:23AM  CLASS ACTION UPDATE for CVET, MYGN, ZEN and PLT: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders GlobeNewswire
09:03AM  Myriad's BRACAnalysis Wins HBOC Risk Assessment Nod in Japan Zacks
Nov-24-19 11:10AM  FINAL DEADLINE TUESDAY: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Myriad Genetics, Inc. and Encourages Investors with Losses in Excess of $250,000 to Contact the Firm ACCESSWIRE
10:25AM  The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of MYGN, DOMO and PLT ACCESSWIRE
10:00AM  2-DAY DEADLINE ALERT: HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Myriad Genetics (MYGN) Investors Who Suffered Significant Losses to Contact Its Attorneys, Application Deadline is Approaching ACCESSWIRE
Nov-23-19 12:00PM  DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Myriad Genetics, Inc. and Encourages Investors to Contact the Firm PR Newswire
10:00AM  3-DAY DEADLINE ALERT: HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Myriad Genetics (MYGN) Investors Who Suffered Significant Losses to Contact Its Attorneys, Application Deadline is Approaching ACCESSWIRE
Nov-22-19 06:01PM  4-DAY DEADLINE ALERT: HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Myriad Genetics (MYGN) Investors Who Suffered Significant Losses to Contact Its Attorneys, Application Deadline is Approaching GlobeNewswire
04:15PM  The Gross Law Firm Announces Class Actions on Behalf of Shareholders of UNIT, MYGN and ET ACCESSWIRE
03:00PM  DEADLINE ALERT - Myriad Genetics, Inc. (MYGN) - Bronstein, Gewirtz & Grossman, LLC Reminds Shareholders of Class Action and Lead Plaintiff Deadline: November 26, 2019 GlobeNewswire
01:15PM  CLASS ACTION UPDATE for UNIT, MYGN and ET: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders ACCESSWIRE
10:49AM  INVESTOR ALERT - Myriad Genetics, Inc. (MYGN) - Bronstein, Gewirtz & Grossman, LLC Reminds Shareholders of Class Action and Lead Deadline: November 26, 2019 ACCESSWIRE
10:37AM  Myriad Deadline Alert: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Myriad Genetics, Inc. To Contact The Firm Newsfile
10:20AM  SHAREHOLDER ALERT: ADTN UNIT MYGN: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines ACCESSWIRE
10:01AM  Myriad Genetics' Test Added in Disease Activity Measure List Zacks
09:00AM  Myriad Genetics Shareholders: November 26, 2019 Filing Deadline in Class Action - Contact Lieff Cabraser ACCESSWIRE
07:39AM  CLASS ACTION DEADLINE: Brodsky & Smith, LLC Reminds Investors of Looming Deadlines to File Lead Plaintiff Motions Related to the Following Companies: MYGN, OSTK, MTCH ACCESSWIRE
Nov-21-19 09:05PM  5-DAY DEADLINE ALERT: HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Myriad Genetics (MYGN) Investors Who Suffered Significant Losses to Contact Its Attorneys, Application Deadline is Approaching ACCESSWIRE
03:26PM  CLASS ACTION UPDATE for SNDL, MYGN, DOMO and ET: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders GlobeNewswire
02:25PM  5-Day Deadline Alert: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Myriad Genetics, Inc. and Encourages Investors with Losses in Excess of $250,000 to Contact the Firm ACCESSWIRE
02:17PM  SHAREHOLDER ALERT: MTCH MYGN TWTR CGC: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines GlobeNewswire
10:44AM  MYGN ALERT: Zhang Investor Law Reminds Investors of NOVEMBER 26 Deadline in Securities Class Action Lawsuit Against Myriad Genetics, Inc. MYGN GlobeNewswire
09:32AM  The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of ADTN, MTCH, MYGN and UA GlobeNewswire
07:05AM  Myriad Genetics Announces Regulatory Approval of the BRACAnalysis® Diagnostic System in Japan for Breast Cancer Patients GlobeNewswire
Nov-20-19 09:20PM  6-Day Deadline Alert: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Myriad Genetics, Inc. and Encourages Investors with Losses in Excess of $250,000 to Contact the Firm ACCESSWIRE
09:05PM  6-DAY DEADLINE ALERT: HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Myriad Genetics (MYGN) Investors Who Suffered Significant Losses to Contact Its Attorneys, Application Deadline is Approaching ACCESSWIRE
06:45PM  The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of MYGN, CC and RUHN ACCESSWIRE
06:15PM  DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Myriad Genetics, Inc. and Encourages Investors to Contact the Firm Business Wire
03:30PM  CLASS ACTION UPDATE for OSTK, MYGN and DOMO: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders ACCESSWIRE
02:52PM  SHAREHOLDER ALERT:  Pomerantz Law Firm Reminds Shareholder with Losses on their Investment in Myriad Genetics, Inc. of Class Action Lawsuit and Upcoming Deadline MYGN GlobeNewswire
11:00AM  The Gross Law Firm Announces Class Actions on Behalf of Shareholders of MYGN, UBER and YJ ACCESSWIRE
10:48AM  INVESTOR ALERT - Myriad Genetics, Inc. (MYGN) - Bronstein, Gewirtz & Grossman, LLC Reminds Shareholders of Class Action and Lead Plaintiff Deadline: November 26, 2019 ACCESSWIRE
07:05AM  The American College of Rheumatology Adds the Vectra® Test to List of Recommended Disease Activity Measures for Rheumatoid Arthritis GlobeNewswire
06:50AM  CLASS ACTION DEADLINE: Brodsky & Smith, LLC Reminds Investors of Looming Deadlines to File Lead Plaintiff Motions Related to the Following Companies: MYGN, OSTK, MTCH ACCESSWIRE
Nov-19-19 09:35PM  7-Day Deadline Alert: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Myriad Genetics, Inc. and Encourages Investors with Losses in Excess of $500,000 to Contact the Firm ACCESSWIRE
08:04PM  7-DAY DEADLINE ALERT: HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Myriad Genetics (MYGN) Investors Who Suffered Significant Losses to Contact Its Attorneys, Application Deadline is Approaching ACCESSWIRE
Myriad Genetics, Inc., a molecular diagnostic company, develops and markets predictive, personalized, and prognostic medicine tests worldwide. The company offers myRisk Hereditary Cancer, a DNA sequencing test for hereditary cancers; BRACAnalysis, a DNA sequencing test to assess the risk of developing breast and ovarian cancer; and riskScore, a personalized medicine tool. It also provides BRACAnalysis CDx, a DNA sequencing test for use in identifying ovarian and HER2 negative metastatic breast cancer patients with deleterious or suspected deleterious germline; GeneSight, a DNA genotyping test to aid psychotropic drug selection for depressed patients; and Vectra, a protein quantification test for assessing the disease activity of rheumatoid arthritis. In addition, the company offers Foresight, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; Prequel, a non-invasive prenatal screening test to screen for severe chromosomal disorders in a fetus; and Prolaris, a RNA expression test for assessing the aggressiveness of prostate cancer. Further, it provides EndoPredict, a RNA expression test for assessing the aggressiveness of breast cancer; myPath Melanoma, a RNA expression test for diagnosing melanoma; and myChoice HRD, a companion diagnostic to measure three modes of homologous recombination deficiency comprising loss of heterozygosity, telomeric allelic imbalance, and large-scale state transitions in cancer cells. Additionally, the company offers biomarker discovery, and pharmaceutical and clinical services to the pharmaceutical, biotechnology, and medical research industries; and operates an internal medicine emergency hospital primarily for internal medicine and hemodialysis. The company has collaboration with AstraZeneca for the development of an indication for BRACAnalysis CDx. Myriad Genetics, Inc. was founded in 1991 and is headquartered in Salt Lake City, Utah.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Lambert NicolePresident, MGLFeb 12Sale19.734,35485,91559,150Feb 12 06:28 PM
Ford AlexanderPresident, MWHFeb 05Sale30.007,273218,190142,438Feb 07 02:39 PM
Ford AlexanderPresident, MWHDec 26Option Exercise15.981,30720,886149,711Dec 27 12:47 PM
GILBERT WALTER PHDDirectorDec 13Buy25.605,860149,99854,150Dec 16 04:16 PM
HENDERSON JOHN TDirectorNov 07Buy23.461,75041,0562,050Nov 07 01:05 PM
HENDERSON JOHN TDirectorNov 07Buy23.465,250123,16764,353Nov 07 01:05 PM
King Gary A.Exec. VP International OpsAug 01Option Exercise23.7360,0001,423,900164,871Aug 02 04:44 PM
Capone Mark ChristopherPresident & C.E.O.Aug 01Option Exercise26.38137,0003,614,330511,505Aug 02 05:45 PM
King Gary A.Exec. VP International OpsAug 01Sale43.4960,0002,609,329134,871Aug 02 04:44 PM
Tobin BernardPresident Crescendo BioScienceAug 01Sale40.0011,712468,480146,040Aug 02 04:40 PM
Riggsbee Richard BryanChief Financial OfficerAug 01Sale41.5025,0001,037,575120,566Aug 02 04:32 PM
Capone Mark ChristopherPresident & C.E.O.Aug 01Sale44.00137,0006,028,000440,833Aug 02 05:45 PM
open in yahoo | open in reuters | open in google